Additionally, Rahatellah et al. observed that patients with post-implant thrombocytopenia (<150  ×  109/l) were almost five times more likely to bleed.14 Similarly, the AVWS results in a loss of large multimers which can be detected using VWF antigen levels (Ag) and ristocetin cofactor activity to calculate the VWF:RCo/VWF:Ag ratio which may be useful in predicting bleeding.9 VWF monitoring may also lend itself to the management of LVAD patients receiving blood products. Here, VWF is linked to Thrombocytopenia.